APYX.NASDAQApyx Medical CORP
10-K: Apyx Medical Corporation Files 10-K Report, Details Financials and Strategic Initiatives
Sentiment:
Annual Results
Apyx Medical Corporation's 10-K filing for 2023 highlights a year of revenue growth, strategic shifts, and ongoing efforts to navigate regulatory challenges and market dynamics.
Capital raiseThe company plans to continue to fund its operations and capital funding needs through existing cash, sales of its products and if necessary additional equity and/or debt financing.On November 22, 2022, the company filed a shelf registration statement providing it the ability to register and sell securities in the aggregate amount up to $100 million.The shelf registration included an embedded ATM facility for up to $40 million.
Worse than expectedThe company experienced reduced demand for its technology following an FDA Safety Communication, despite new clearances.The company incurred a loss from operations of $17.3 million for the year ended December 31, 2023.Gross profit margins decreased slightly due to changes in product mix, customer mix, and higher material costs.
Summary
- Apyx Medical Corporation's 10-K filing for the year ended December 31, 2023, reveals a 17.6% increase in total revenue, reaching $52.3 million, compared to $44.5 million in 2022.
- The Advanced Energy segment saw a 17.9% revenue increase, driven by domestic sales of the new Apyx One Console and increased handpiece volume.
- The OEM segment also experienced growth, with a 16.3% increase in revenue due to higher sales volume to existing customers and new supply arrangements.
- The company incurred a loss from operations of $17.3 million and used $5.2 million of cash in operations, inclusive of an $8.1 million tax refund.
- As of December 31, 2023, Apyx had $43.7 million in cash and cash equivalents.
- Apyx continues to focus on the cosmetic surgery market with its Renuvion technology, supported by a direct sales force and international distributors.
- The company received multiple FDA 510(k) clearances for its Renuvion handpieces, expanding their approved uses.
- Apyx entered into a new $45 million credit agreement with Perceptive Credit Holdings, replacing the previous MidCap Credit Agreement.
- The company sold its Clearwater, FL facility for $7.65 million and entered into a 10-year leaseback agreement.
- Management estimates that Apyx products have been sold in more than 60 countries.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While there is revenue growth and strategic progress, the company is still operating at a loss and faces significant risks. The sentiment is neutral, with both positive and negative factors influencing the outlook.
Positives
- Apyx Medical experienced significant revenue growth in both its Advanced Energy and OEM segments.
- The company successfully secured a new credit facility, improving its financial position.
- Multiple FDA clearances were obtained, expanding the market for Renuvion products.
- The sale-leaseback of the Clearwater facility generated a gain of $2.7 million.
- The company received a substantial tax refund, boosting its cash reserves.
- Apyx continues to expand its global reach, with products sold in over 60 countries.
Negatives
- Apyx Medical incurred a loss from operations of $17.3 million for the year ended December 31, 2023.
- The company experienced reduced demand for its technology following an FDA Safety Communication, despite new clearances.
- Gross profit margins decreased slightly due to changes in product mix, customer mix, and higher material costs.
- The company incurred a $3.1 million loss on the extinguishment of debt related to the MidCap Credit Agreement.
- The company continues to experience reduced demand for the adoption and utilization of its technology.
Risks
- The company faces risks related to maintaining sufficient liquidity and meeting debt covenants.
- There is a risk of reduced demand for cosmetic procedures due to economic conditions and the rise of GLP-1 medications.
- Apyx is subject to intense competition in the medical device industry.
- The company relies on sole-source suppliers for some raw materials, creating supply chain vulnerabilities.
- The company is subject to ongoing regulatory scrutiny and potential adverse actions by the FDA and other agencies.
- The company is involved in multiple legal actions relating to the use of its technology.
- The company is exposed to risks related to cybersecurity breaches and data privacy regulations.
- The company is subject to governmental export controls and economic sanctions that could impair its ability to compete in international markets.
Future Outlook
Apyx plans to continue funding operations through existing cash, product sales, and potential additional equity or debt financing. The company aims to increase adoption of its Advanced Energy technology and utilization of its handpieces, while also focusing on strategic initiatives to drive long-term growth in the cosmetic surgery market.
Management Comments
- Management estimates that our products have been sold in more than 60 countries.
- Management believes that the actions already taken, including replacing the MidCap Credit Agreement with the Perceptive Credit Agreement, alleviated the conditions that previously raised substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of our Consolidated Financial Statements.
Industry Context
The cosmetic surgery market is experiencing steady growth, driven by social media, societal influence, and increasing disposable income. Liposuction procedures are growing, and Apyx's Renuvion technology is positioned to address skin laxity issues, particularly in the context of weight loss trends. The company believes it has competitive advantages due to its unique technology, product quality, and clinical support.
Comparison to Industry Standards
- Apyx competes with companies offering RF-based, argon plasma, and CO2 laser products in the aesthetics market.
- Unlike competitors, Apyx has four specific FDA indications for its helium-based plasma products.
- The company's focus on the cosmetic surgery market aligns with industry trends in body contouring and addressing skin laxity.
- Apyx's technology is supported by over eighty-five peer-reviewed journal articles, book chapters, abstracts, and posters, indicating a strong scientific foundation.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer, Treasurer and Secretary | Tara Semb | Matthew Hill | 2023-12-04 | Tara Semb departed the role and Matthew Hill was appointed. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Clawback Policy | The Board of Directors adopted a clawback policy to provide for the recovery of erroneously awarded incentive-based compensation from certain executive officers. | 2023-10-02 | This policy enhances corporate governance by ensuring accountability and compliance with financial reporting requirements. |
Legal Proceedings
- The company is involved in a number of legal actions relating to the use of its technology.
- The company is in a dispute with one of its insurance carriers regarding the total level of coverage available.
- The company recorded an estimated loss of $1.3 million related to product liability lawsuits filed in connection with off-label use of Renuvion products.
Related Party Transactions
- Some relatives of Nikolay Shilev, Apyx Bulgaria's Managing Director, are employees of the company.
- The partner in the company's China joint venture is also a supplier of the company.
Stakeholder Impact
- Shareholders face the risk of dilution from potential equity raises and volatility in the stock price.
- Employees are subject to the company's performance and financial stability.
- Customers may be impacted by supply chain issues and regulatory changes.
- Suppliers are subject to the company's financial health and ability to meet its obligations.
- Creditors are exposed to the company's ability to meet its debt obligations.
Next Steps
- The company will continue to focus on increasing the adoption of its Advanced Energy technology and utilization of its handpieces.
- Apyx will continue to develop a clinical and regulatory strategy, and corresponding marketing campaigns, to support its market focus.
- The company will continue to expand the reach of its global medical affairs team to provide clinical support to customers.
- Apyx will continue to make substantial investments in the development and marketing of its Renuvion technology.
Key Dates
| Date | Description |
|---|---|
| 2012-07-31 | Date of the Two Thousand Twelve Share Incentive Plan |
| 2015-07-31 | Date of the Two Thousand Fifteen Executive And Employee Stock Option Plan |
| 2017-08-31 | Date of the A2017 Executive and Employee Stock Option Plan |
| 2019-08-31 | Date of the A2019 Share Incentive Plan |
| 2021-08-31 | Date of the A2021 Share Incentive Plan |
| 2022-11-22 | Filing date of shelf registration statement |
| 2023-02-17 | Date of the MidCap Credit Agreement |
| 2023-02-27 | FDA 510(k) clearance for Renuvion APR handpiece for soft tissue coagulation/contraction |
| 2023-03-14 | Date of Purchase and Sale Agreement for Clearwater facility |
| 2023-04-28 | FDA 510(k) clearance for Renuvion APR handpiece for coagulation of subcutaneous soft tissues following liposuction |
| 2023-05-08 | Closing date of Purchase Agreement and leaseback of Clearwater facility |
| 2023-06-14 | FDA 510(k) clearance for Renuvion Micro handpiece |
| 2023-08-10 | Company received $8.1 million from the IRS |
| 2023-08-31 | Date of the A2023 Share Incentive Plan |
| 2023-11-08 | Date of the Perceptive Credit Agreement |
| 2023-12-31 | End of fiscal year 2023 |
| 2024-03-21 | Date of the Renuvion Product Liability Matters Minimum and Maximum |
Keywords
Renuvion, Helium Plasma Technology, Medical Devices, Cosmetic Surgery, FDA Clearance, Financial Results, Advanced Energy, OEM, Credit Agreement, Supply Chain, Regulatory Compliance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.